Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
INSERM manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data indicates 1 pending office action currently active. This action is being reviewed by 1 distinct examiner in 1 distinct art unit, showing a specific focus for the organization's current pharmaceutical or biological applications. This concentration suggests that the filings are being evaluated within a single specialized group at the USPTO.
The busiest examiner for the portfolio is STAVROU, CONSTANTINA E, who is responsible for 1 busiest examiner pending action. This action accounts for the total of 1 pending office action for the portfolio. The concentration in the distinct art unit suggests that the current filings are being evaluated within a specific technical specialty. For practitioners, this highlights the importance of understanding the examiner's specific technical standards, as their review will determine the outcome for the entirety of the organization's active prosecution.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
| MEYERING, SHABANA SHABBEER | 1 | 68.5% | +45.1% |
| ALDARRAJI, ZAINAB MOHAMMED | 1 | 67.4% | +18.7% |
| FARAG, AMAL ALY | 1 | 68.0% | +38.4% |
| GRASER, JENNIFER E | 1 | 76.8% | +23.2% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255885 | MICRO-DEVICE TRACKING AND VIZUALISATION SYSTEM | FARAG, AMAL ALY | 78d overdue |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 15d overdue |
| 17918686 | METHOD FOR PREDICTING THE RETURN TO FUNCTIONAL AUTONOMY IN A SUBJECT SUFFERING FROM AN ACUTE EVENT | IVICH, FERNANDO NMN | 27d |
| 18248120 | COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255885 | MICRO-DEVICE TRACKING AND VIZUALISATION SYSTEM | FARAG, AMAL ALY | 78d overdue |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 15d overdue |
| 18256706 | ULTRASOUND DEVICE TRACKING SYSTEM | ALDARRAJI, ZAINAB MOHAMMED | 8d overdue |
| 17918686 | METHOD FOR PREDICTING THE RETURN TO FUNCTIONAL AUTONOMY IN A SUBJECT SUFFERING FROM AN ACUTE EVENT | IVICH, FERNANDO NMN | 27d |
| 18692037 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | STONEBRAKER, ALYSSA RAE | — |
| 18294577 | HYBRID PROMOTERS FOR GENE EXPRESSION IN MUSCLES AND IN THE CNS | MEYERING, SHABANA SHABBEER | — |
| 18248120 | COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | GRASER, JENNIFER E | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1635 | 1 |
| 3797 | 1 |
| 3798 | 1 |
| 1645 | 1 |
| 1678 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692037 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18294577 | HYBRID PROMOTERS FOR GENE EXPRESSION IN MUSCLES AND IN THE CNS | MEYERING, SHABANA SHABBEER | 1635 | §103Other | Final Rejection | — | Pending | Feb 02, 2024 |
| 18256706 | ULTRASOUND DEVICE TRACKING SYSTEM | ALDARRAJI, ZAINAB MOHAMMED | 3797 | §103 | Final Rejection | 8d overdue | Pending | Jun 09, 2023 |
| 18255885 | MICRO-DEVICE TRACKING AND VIZUALISATION SYSTEM | FARAG, AMAL ALY | 3798 | §101§103 | Non-Final OA | 78d overdue | Pending | Jun 05, 2023 |
| 18248120 | COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | GRASER, JENNIFER E | 1645 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17918686 | METHOD FOR PREDICTING THE RETURN TO FUNCTIONAL AUTONOMY IN A SUBJECT SUFFERING FROM AN ACUTE EVENT | IVICH, FERNANDO NMN | 1678 | §101§103§112 | Non-Final OA | 27d | Pending | Oct 13, 2022 |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 1631 | §102§103 | Final Rejection | 15d overdue | Pending | Jul 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialINSERM has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Alyssa Rae Stonebraker has the most, with 1 of INSERM's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
